EP2783388A1 - Kisspeptin-54 detection by tandem mass spectrometry - Google Patents
Kisspeptin-54 detection by tandem mass spectrometryInfo
- Publication number
- EP2783388A1 EP2783388A1 EP12851916.2A EP12851916A EP2783388A1 EP 2783388 A1 EP2783388 A1 EP 2783388A1 EP 12851916 A EP12851916 A EP 12851916A EP 2783388 A1 EP2783388 A1 EP 2783388A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- kisspeptin
- ions
- sample
- derived peptides
- ion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
- H01J49/0031—Step by step routines describing the use of the apparatus
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/0027—Methods for using particle spectrometers
- H01J49/0036—Step by step routines describing the handling of the data generated during a measurement
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
- G01N2333/4704—Inhibitors; Supressors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/004—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
- H01J49/00—Particle spectrometers or separator tubes
- H01J49/004—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn
- H01J49/0045—Combinations of spectrometers, tandem spectrometers, e.g. MS/MS, MSn characterised by the fragmentation or other specific reaction
Definitions
- the invention relates to the quantitative measurement of kisspeptin-54 and kisspeptin-54-derived peptides.
- the invention relates to methods for quantitative measurement of kisspeptin-54 and kisspeptin-54-derived peptides by HPLC- tandem mass spectrometry.
- the kisspeptin-54 peptide is essential for sexual reproduction and it suppresses cancer metastasis. It is also known as metastin, kisspeptin 1-54, KP-54, and KiSS-1 (68- 121). Kisspeptin-54 is the carboxamide fragment of residues 68-121 of the protein KiSS-1, which in turn is encoded by the KiSS-1 gene. Kisspeptin-54 potently and selectively stimulates the G-protein-coupled receptor 54 (GPR54) to signal secretion of gonadotropin- releasing hormone (GnRH). Rhythmical secretions of GnRH initiate puberty, coordinate ovulation, and maintain overall reproductive function. Kisspeptin-54 is known to suppress the progression of melanomas and breast cancers. It is postulated that kisspeptin-54 suppresses metastasis by inhibiting chemotaxis and invasion of cancer cells.
- Human kisspeptin-54 (CAS No: [374683-24-6]) consists of 54 amino acids with a molecular weight of about 5857.5 g/mol and a monoisotopic mass of about 5854.0 g/mol. It is a peptide amide cleavage product containing the amino acid residues from 68 to 121 of the 138 amino acid KiSS-1 protein. Other bioactive peptides that result from cleavage of KiSS-1 are kisspeptin- 14 (KP-14, 41-54), kisspeptin- 13 (KP-13, residues 42-54), and kisspeptin- 10 (KP-10; residues 45-54). [0006] Kisspeptin-54 has been identified using tandem mass spectrometry. See e.g., Kotani, M., et al, J. Biol. Chem. 2001, 276(37), 34631-6 (isolated); Dhillo, W., et al, J. Clin
- the present invention provides methods of determining by mass spectrometry the amount in a sample of one or more kisspeptin-54-derived peptides selected from the group consisting of kisspeptin-54, kisspeptin-53, kisspeptin-52, kisspeptin- 54(R14P), kisspeptin-53(R14P), and kisspeptin-52(R14P).
- These methods include subjecting the sample to ionization under conditions suitable to produce one or more multiply charged kisspeptin-54-derived peptide ions detectable by mass spectrometry; determining by mass spectrometry the amount of one or more ions from each of the one or more kisspeptin-54- derived peptides; and using the amount of the determined ions to determine the amounts of the corresponding one or more kisspeptin-54-derived peptides in the sample.
- the methods further include, prior to ionization, enriching the concentration of the kisspeptin-54-derived peptides with an antibody specific for the N- terminal portion of kisspeptin-54.
- the methods further includes adding an organic solvent, such as methanol, to the sample in an amount sufficient to precipitate one or more components from said sample, so as to enrich the concentration of the kisspeptin-54-derived peptides.
- ions are determined from kisspeptin-54, kisspeptin-53, and kisspeptin-52. In some embodiments, ions are determined from kisspeptin-54(R14P), kisspeptin-53(R14P), and kisspeptin-52(R14P).
- kisspeptin-54-derived peptides from the sample are chemically modified prior to ionization.
- At least one of the multiply charged ions generated from the kisspeptin-54-derived peptides is selected from the group of ions with a charge consisting of 4+, 5+, 6+, or 7+.
- the determined kisspeptin-54-derived peptides are selected from the group consisting of kisspeptin-54, kisspeptin-53, kisspeptin-52.
- multiply charged kisspeptin-54 ions may be selected from the group of ions with m/z of 1172.4 ⁇ 0.5, 977.2 ⁇ 0.5, and 837.7 ⁇ 0.5.
- multiply charged kisspeptin-54(R14P) ions may be selected from the group of ions with m/z of 1450.5 ⁇ 0.5, 1160.6 ⁇ 0.5, and 967.3 ⁇ 0.5.
- multiply charged kisspeptin-53 ions may be selected from the group of ions with m/z of 1143.2 ⁇ 0.5, 952.7 ⁇ 0.5, and 816.9 ⁇ 0.5.
- multiply charged kisspeptin-52 ions may be selected from the group of ions with m/z of 1112.0 ⁇ 0.5, and 926.6 ⁇ 0.5.
- mass spectrometry is tandem mass spectrometry.
- Embodiments utilizing tandem mass spectrometry comprise fragmenting one or more of the multiply charged kisspeptin-54-derived peptide ions into kisspeptin-54-derived peptide fragment ions.
- multiply charged kisspeptin-54 ions with m/z of 977.2 ⁇ 0.5 may be fragmented into one or more ions selected from the group consisting of ions with m/z of 1083.6 ⁇ 0.5 and 903.1 ⁇ 0.5; multiply charged kisspeptin-54 ions with m/z of 837.7 ⁇ 0.5 may be fragmented into an ion with m/z of 977.2 ⁇ 0.5.
- multiply charged kisspeptin-54(R14P) ions with m/z of 1160.6 ⁇ 0.5 may be fragmented into an ion with m/z of 1071.6 ⁇ 0.5; multiply charged kisspeptin-54(R14P) ions with m/z of 967.3 ⁇ 0.5 may be fragmented into an ion with m/z of 1071.6 ⁇ 0.5.
- multiply charged kisspeptin-53 ions with m/z of 1143.2 ⁇ 0.5 may be fragmented into an ion with m/z of 1053.9 ⁇ 0.5; multiply charged kisspeptin-53 ions with m/z of 952.7 ⁇ 0.5 may be fragmented into one or more ions selected from the group of ions with m/z of 1054.1 ⁇ 0.5 and 878.5 ⁇ 0.5; and multiply charged kisspeptin-53 ions with m/z of 816.7 ⁇ 0.5 may be fragmented into an ion with m/z of 878.3 ⁇ 0.5.
- multiply charged kisspeptin-52 ions with m/z of 1112.0 ⁇ 0.5 may be fragmented into one or more ions selected from the group consisting of ions with m/z of 1278.2 ⁇ 0.5 and 1022.9; multiply charged kisspeptin-52 ions with m/z of 926.8 ⁇ 0.5 may be fragmented into an ion with m/z of 1022.9 ⁇ 0.5.
- a sample is subjected to one or more processing steps prior to ionization.
- the processing steps include one or more purification steps.
- the processing steps include adding aqueous formic acid to the sample.
- the processing steps include adding an organic solvent, such as methanol, to the sample in an amount sufficient to precipitate one or more components from said sample; centrifuging the organic solvent-sample mixture, wherein a portion of kisspeptin-54-derived peptides from the sample remain in the supernatant; and collecting the supernatant for further processing or ionization.
- the processing steps include applying the sample to an anion or cation exchange column under conditions suitable to retain kisspeptin-54-derived peptides on the column; eluting kisspeptin-54-derived peptides from the column; and collecting the eluted kisspeptin-54-derived peptides for further processing or ionization.
- the processing steps include
- immunopurification comprises capture and extraction of one or more of kisspeptin-54-derived peptides using anti-kisspeptin-54- derived peptides antibodies specific for the N-terminus of kisspeptin-54.
- the processing steps comprise solid phase extraction (SPE). In some embodiments, the processing steps comprise high performance liquid chromatography (HPLC).
- SPE solid phase extraction
- HPLC high performance liquid chromatography
- the invention provides methods of reducing the degradation of kisspeptin-54-derived peptides in body fluid sample from a patient. These methods include acidifying a body fluid sample, treating a body fluid sample with an agent under conditions sufficient to precipitate proteins from said body fluid sample, or both.
- acidifying said body fluid sample comprises acidifying with aqueous formic acid.
- the protein precipitation agent comprises an organic solvent, such as methanol. In some related embodiments, the ratio of the volume of the organic solvent to the volume of the biological sample is about 3: 1.
- the invention provides methods of measuring degradation of kisspeptin-54 in a biological fluid sample from a patient.
- These methods include subjecting a body fluid sample from a patient to ionization under conditions suitable to produce one or more multiply charged ions detectable by mass spectrometry from kisspeptin-54 and one or more kisspeptin-54 derivation products selected from the group consisting of kisspeptin-53 and kisspeptin-52; determining by mass spectrometry the amount of one or more ions of kisspeptin-54 and one or more kisspeptin-54 derivation products selected from the group consisting of kisspeptin-53 and kisspeptin-52; and using the amounts of ions determined in step b to determine the amounts of kisspeptin-54 and kisspeptin-54 derivation products in the sample.
- Similar methods are provided for measuring degradation of kisspeptin-54(R14P) in a biological fluid sample from a patient. These methods include subjecting a biological fluid sample from a patient to ionization under conditions suitable to produce one or more multiply charged ions detectable by mass spectrometry from kisspeptin-54(R14P) and one or more kisspeptin-54(R14P) derivation products selected from the group consisting of kisspeptin- 53(R14P) and kisspeptin-52(R14P); determining by mass spectrometry the amount of one or more ions of kisspeptin-54(R14P) and one or more kisspeptin-54(R14P) derivation products selected from the group consisting of kisspeptin-53 (R14P) and kisspeptin-52(R14P); and using the amounts of ions determined in step b to determine the amounts of kisspeptin- 54(R14P) and kisspeptin-54(R14P) derivation products
- the invention provides methods of diagnosing or predicting risk of developing preeclampsia. These methods include providing a body fluid or tissue sample obtained from a patient; subjecting the body fluid or tissue sample to one or more processing steps to generate a processed sample comprising one or more kisspeptin-54-derived peptides selected from the group consisting of kisspeptin-54, kisspeptin-53, kisspeptin-52, kisspeptin- 54(R14P), kisspeptin-53(R14P), and kisspeptin-52(R14P); subjecting the processed sample to ionization under conditions suitable to produce one or more multiply charged ions detectable by mass spectrometry; determining by mass spectrometry the amount of one or more ions from one or more kisspeptin-54-derived peptides; and using the determined ion amounts to determine the amount of kisspeptin-54 or kisspeptin-54(R14P) in the sample.
- the invention provides one or more substantially isolated polypeptides with amino acid sequences consisting of the sequences identified as SEQ ID No.:2 and SEQ ID No.:3, or proline variants thereof.
- tandem mass spectrometry may be conducted by any method known in the art, including for example, multiple reaction monitoring, precursor ion scanning, or product ion scanning.
- two or more of these components may be connected in an on-line fashion to allow for automated sample processing and analysis.
- mass spectrometry is preferably performed in positive ion mode.
- mass spectrometry is performed in negative ion mode.
- Various ionization sources including for example atmospheric pressure chemical ionization (APCI), electrospray ionization (ESI), and heated ESI, may be used in embodiments of the present invention.
- APCI atmospheric pressure chemical ionization
- ESI electrospray ionization
- heated ESI heated ESI
- kisspeptin-54-derived peptides are ionized using heated ESI in positive ion mode.
- a separately detectable internal standard is provided in the sample, the amount of which is also determined in the sample.
- all or a portion of both the analyte(s) of interest and the internal standard present in the sample is ionized to produce a plurality of ions detectable in a mass
- the presence or amount of ions generated from the analyte of interest may be related to the presence of amount of analyte of interest in the sample.
- the amount of one or more kisspeptin-54-derived peptides in a sample may be determined by comparison to one or more external reference standards.
- Exemplary external reference standards include blank plasma or serum spiked with a kisspeptin-54-derived peptide or an isotopically labeled variant thereof (such as isotopically labeled kisspeptin-54 and isotopically labeled kisspeptin-54(R14P)).
- a kisspeptin-54-derived peptide or an isotopically labeled variant thereof such as isotopically labeled kisspeptin-54 and isotopically labeled kisspeptin-54(R14P)
- R14P isotopically labeled kisspeptin-54
- kisspeptin-54-derived peptide refers to intact kisspeptin- 54 and peptide fragments whose amino acid sequence is found within the amino acid sequence of kisspeptin-54, and all polymorphs thereof.
- One known polymorph of kisspeptin- 54 includes a proline replacement for the arginine at position 14. This polymorph is described herein as kisspeptin-54 (proline variant) or kisspeptin-54(R14P).
- Kisspeptin-54- derived peptides may possess one or more of the following attributes: naturally occurring, chemically synthesized, isotopically labeled, and chemically modified.
- Isotopic labeling and/or chemical modification may be conducted by any of several techniques known by those of skill in the art.
- Other exemplary kisspeptin-54 derived peptides include kisspeptin-53, kisspeptin-52, and their protein variants.
- kisspeptin-54" refers to a 54 amino acid peptide with the sequence shown as SEQ ID No.:l in Figure 1A.
- kisspeptin-53 refers to a 53 amino acid peptide with the sequence shown as SEQ ID No.:2 in Figure IB.
- kisspeptin-52 refers to a 52 amino acid peptide with the sequence shown as SEQ ID No.: 3 in Figure 1C.
- the term "isolated" as applied to a polypeptide means a polypeptide that has been separated from components that naturally accompany it. Typically, the polypeptide is substantially isolated when it is at least 60%, by weight, free from the proteins and naturally occurring organic molecules with which it is naturally associated.
- the definition also extends to a polypeptide separated from its flanking amino acids (e.g., for an amino acid sequence, isolated refers to a sequence that is free from the flanking amino acids with which the sequence is naturally associated in a polypeptide).
- the polypeptide is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, isolated.
- An isolated polypeptide may be obtained by standard techniques, for example, by extraction from a natural source (e.g., purification from a cell or body fluid), by expression of a recombinant nucleic acid encoding the peptide; or fusion protein thereof, by chemically synthesizing the polypeptide. Purity can be measured by any appropriate method, e.g., by column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis. [0039] As used herein, the term "purification” or “purifying” does not refer to removing all materials from the sample other than the analyte(s) of interest. Instead, purification refers to a procedure that enriches the amount of one or more analytes of interest relative to other components in the sample that may interfere with detection of the analyte of interest.
- Purification of the sample by various means may allow relative reduction of one or more interfering substances, e.g., one or more substances that may or may not interfere with the detection of selected parent or daughter ions by mass spectrometry. Relative reduction as this term is used does not require that any substance, present with the analyte of interest in the material to be purified, is entirely removed by purification.
- immunopurification refers to a purification procedure that utilizes antibodies, including polyclonal or monoclonal antibodies, to enrich the one or more analytes of interest. Immunopurification can be performed using any of the immunopurification methods well known in the art. Often the immunopurification procedure utilizes antibodies bound, conjugated or otherwise attached to a solid support, for example a column, well, tube, gel, capsule, particle or the like. Immunopurification as used herein includes without limitation procedures often referred to in the art as
- immunoparticle refers to a capsule, bead, gel particle or the like that has antibodies bound, conjugated or otherwise attached to its surface (either on and/or in the particle).
- immunoparticles are sepharose or agarose beads.
- immunoparticles are glass, plastic or silica beads, or silica gel.
- the term "anti-kisspeptin-54-derived peptide antibody” refers to any polyclonal or monoclonal antibody that has an affinity for a kisspeptin-54-derived peptide.
- the specificity of kisspeptin-54-derived peptide antibodies to chemical species other than the kisspeptin-54-derived peptide may vary; for example in certain preferred embodiments the anti-kisspeptin-54-derived peptide antibodies are specific for the kisspeptin-54-derived peptide and thus have little or no affinity for chemical species other than the kisspeptin-54-derived peptide, whereas in other preferred embodiments the anti- kisspeptin-54-derived peptide antibodies are non-specific and thus bind certain chemical species other than the kisspeptin-54-derived peptide.
- sample refers to any sample that may contain an analyte of interest.
- body fluid means any fluid that can be isolated from the body of an individual.
- body fluid may include blood, plasma, serum, bile, saliva, urine, tears, perspiration, and the like.
- the sample comprises a body fluid sample; preferably plasma or serum, from a patient.
- solid phase extraction refers to a process in which a chemical mixture is separated into components as a result of the affinity of components dissolved or suspended in a solution (i.e., mobile phase) for a solid through or around which the solution is passed (i.e., solid phase).
- a solution i.e., mobile phase
- the solid phase may be retained by the solid phase resulting in a purification of the analyte in the mobile phase.
- the analyte may be retained by the solid phase, allowing undesired components of the mobile phase to pass through or around the solid phase.
- SPE including TFLC
- TFLC may operate via a unitary or mixed mode mechanism.
- Mixed mode mechanisms utilize ion exchange and hydrophobic retention in the same column; for example, the solid phase of a mixed-mode SPE column may exhibit strong anion exchange and hydrophobic retention; or may exhibit column exhibit strong cation exchange and hydrophobic retention.
- chromatography refers to a process in which a chemical mixture carried by a liquid or gas is separated into components as a result of differential distribution of the chemical entities as they flow around or over a stationary liquid or solid phase.
- liquid chromatography means a process of selective retardation of one or more components of a fluid solution as the fluid uniformly percolates through a column of a finely divided substance, or through capillary passageways. The retardation results from the distribution of the components of the mixture between one or more stationary phases and the bulk fluid, (i.e., mobile phase), as this fluid moves relative to the stationary phase(s).
- liquid chromatography examples include normal phase liquid chromatography (NPLC), reverse phase liquid chromatography (RPLC), high performance liquid chromatography (HPLC), ultra high performance liquid chromatography (UHPLC), and turbulent flow liquid chromatography (TFLC) (sometimes known as high turbulence liquid chromatography (HTLC) or high throughput liquid chromatography).
- NPLC normal phase liquid chromatography
- RPLC reverse phase liquid chromatography
- HPLC high performance liquid chromatography
- UHPLC ultra high performance liquid chromatography
- TFLC turbulent flow liquid chromatography
- HTLC high turbulence liquid chromatography
- high throughput liquid chromatography high throughput liquid chromatography
- Ultra high pressure liquid chromatography refers to liquid chromatography in which the degree of separation is increased by forcing the mobile phase under high pressure through a stationary phase, typically a densely packed column with a stationary phase comprising packing particles that have an average diameter of than 2 ⁇ .
- TFLC has been applied in the preparation of samples containing two unnamed drugs prior to analysis by mass spectrometry. See, e.g., Zimmer et al., J Chromatogr A 854: 23-35 (1999); see also, U.S. Patents No. 5,968,367, 5,919,368, 5,795,469, and 5,772,874, which further explain TFLC. Persons of ordinary skill in the art understand “turbulent flow”. When fluid flows slowly and smoothly, the flow is called “laminar flow”.
- fluid moving through an HPLC column at low flow rates is laminar.
- laminar flow the motion of the particles of fluid is orderly with particles moving generally in straight lines.
- the inertia of the water overcomes fluid frictional forces and turbulent flow results.
- Fluid not in contact with the irregular boundary "outruns" that which is slowed by friction or deflected by an uneven surface.
- a fluid is flowing turbulently, it flows in eddies and whirls (or vortices), with more "drag” than when the flow is laminar.
- Many references are available for assisting in determining when fluid flow is laminar or turbulent (e.g., Turbulent Flow Analysis: Measurement and Prediction, P.S. Bernard & J.M. Wallace, John Wiley & Sons, Inc., (2000); An Introduction to Turbulent Flow, Jean Mathieu & Julian Scott,
- the term "gas chromatography” or "GC” refers to chromatography in which the sample mixture is vaporized and injected into a stream of carrier gas (as nitrogen or helium) moving through a column containing a stationary phase composed of a liquid or a particulate solid and is separated into its component compounds according to the affinity of the compounds for the stationary phase.
- carrier gas as nitrogen or helium
- the term “large particle column” or “extraction column” refers to a chromatography column containing an average particle diameter greater than about 50 ⁇ . As used in this context, the term “about” means ⁇ 10%.
- analytical column refers to a chromatography column having sufficient chromatographic plates to effect a separation of materials in a sample that elute from the column sufficient to allow a determination of the presence or amount of an analyte. Such columns are often distinguished from “extraction columns", which have the general purpose of separating or extracting retained material from non-retained materials in order to obtain a purified sample for further analysis. As used in this context, the term “about” means ⁇ 10%. In a preferred embodiment the analytical column contains particles of about 5 ⁇ in diameter.
- the terms “on-line” and “inline”, for example as used in “on-line automated fashion” or “on-line extraction” refers to a procedure performed without the need for operator intervention.
- the term “off-line” as used herein refers to a procedure requiring manual intervention of an operator.
- MS mass spectrometry
- MS refers to an analytical technique to identify compounds by their mass.
- MS refers to methods of filtering, detecting, and measuring ions based on their mass-to-charge ratio, or "m/z”.
- MS technology generally includes (1) ionizing the compounds to form charged compounds; and (2) detecting the molecular weight of the charged compounds and calculating a mass-to-charge ratio. The compounds may be ionized and detected by any suitable means.
- a “mass spectrometer” generally includes an ionizer and an ion detector.
- one or more molecules of interest are ionized, and the ions are subsequently introduced into a mass spectrometric instrument where, due to a combination of magnetic and electric fields, the ions follow a path in space that is dependent upon mass (“m”) and charge (“z").
- mass m
- z charge
- the term "operating in negative ion mode” refers to those mass spectrometry methods where negative ions are generated and detected.
- the term "operating in positive ion mode” as used herein, refers to those mass spectrometry methods where positive ions are generated and detected.
- the term "ionization” or “ionizing” refers to the process of generating an analyte ion having a net electrical charge equal to one or more electron units. Negative ions are those having a net negative charge of one or more electron units, while positive ions are those having a net positive charge of one or more electron units.
- EI electron ionization
- CI chemical ionization
- a reagent gas e.g. ammonia
- analyte ions are formed by the interaction of reagent gas ions and analyte molecules.
- the term "fast atom bombardment” or “FAB” refers to methods in which a beam of high energy atoms (often Xe or Ar) impacts a non-volatile sample, desorbing and ionizing molecules contained in the sample.
- Test samples are dissolved in a viscous liquid matrix such as glycerol, thioglycerol, m-nitrobenzyl alcohol, 18-crown-6 crown ether, 2-nitrophenyloctyl ether, sulfolane, diethanolamine, and triethanolamine.
- a viscous liquid matrix such as glycerol, thioglycerol, m-nitrobenzyl alcohol, 18-crown-6 crown ether, 2-nitrophenyloctyl ether, sulfolane, diethanolamine, and triethanolamine.
- matrix-assisted laser desorption ionization refers to methods in which a non- volatile sample is exposed to laser irradiation, which desorbs and ionizes analytes in the sample by various ionization pathways, including photo- ionization, protonation, deprotonation, and cluster decay.
- MALDI matrix-assisted laser desorption ionization
- the sample is mixed with an energy-absorbing matrix, which facilitates desorption of analyte molecules.
- the term "surface enhanced laser desorption ionization” or “SELDI” refers to another method in which a non- volatile sample is exposed to laser irradiation, which desorbs and ionizes analytes in the sample by various ionization pathways, including photo- ionization, protonation, deprotonation, and cluster decay.
- SELDI surface enhanced laser desorption ionization
- the sample is typically bound to a surface that preferentially retains one or more analytes of interest.
- this process may also employ an energy-absorbing material to facilitate ionization.
- ESI electrospray ionization
- a solution is passed along a short length of capillary tube, to the end of which is applied a high positive or negative electric potential.
- Solution reaching the end of the tube is vaporized (nebulized) into a jet or spray of very small droplets of solution in solvent vapor.
- This mist of droplets flows through an evaporation chamber.
- Heated ESI is similar, but includes a heat source for heating the sample while in the capillary tube.
- APCI atmospheric pressure chemical ionization
- mass spectrometry methods that are similar to ESI; however, APCI produces ions by ion-molecule reactions that occur within a plasma at atmospheric pressure.
- the plasma is maintained by an electric discharge between the spray capillary and a counter electrode.
- ions are typically extracted into the mass analyzer by use of a set of differentially pumped skimmer stages.
- a counterflow of dry and preheated N 2 gas may be used to improve removal of solvent.
- the gas-phase ionization in APCI can be more effective than ESI for analyzing less-polar species.
- the term "atmospheric pressure photoionization” or "APPI" as used herein refers to the form of mass spectrometry where the mechanism for the photoionization of molecule M is photon absorption and electron ejection to form the molecular ion M+. Because the photon energy typically is just above the ionization potential, the molecular ion is less susceptible to dissociation. In many cases it may be possible to analyze samples without the need for chromatography, thus saving significant time and expense. In the presence of water vapor or protic solvents, the molecular ion can extract H to form MH+. This tends to occur if M has a high proton affinity.
- ICP inductively coupled plasma
- field desorption refers to methods in which a non-volatile test sample is placed on an ionization surface, and an intense electric field is used to generate analyte ions.
- the term "desorption” refers to the removal of an analyte from a surface and/or the entry of an analyte into a gaseous phase.
- Laser desorption thermal desorption is a technique wherein a sample containing the analyte is thermally desorbed into the gas phase by a laser pulse.
- the laser hits the back of a specially made 96-well plate with a metal base.
- the laser pulse heats the base and the heat causes the sample to transfer into the gas phase.
- the gas phase sample is then drawn into the mass spectrometer.
- selective ion monitoring is a detection mode for a mass spectrometric instrument in which only ions within a relatively narrow mass range, typically about one mass unit, are detected.
- multiple reaction mode is a detection mode for a mass spectrometric instrument in which a precursor ion and one or more fragment ions are selectively detected.
- the term "lower limit of quantification”, “lower limit of quantitation” or “LLOQ” refers to the point where measurements become quantitatively meaningful.
- the analyte response at this LOQ is identifiable, discrete and reproducible with a relative standard deviation (RSD %) of less than 20% and an accuracy of 85% to 115%.
- the term "limit of detection” or "LOD" is the point at which the measured value is larger than the uncertainty associated with it.
- the LOD is the point at which a value is beyond the uncertainty associated with its measurement and is defined as three times the RSD of the mean at the zero concentration.
- an “amount" of an analyte in a body fluid sample refers generally to an absolute value reflecting the mass of the analyte detectable in volume of sample.
- an amount also contemplates a relative amount in comparison to another analyte amount.
- an amount of an analyte in a sample can be an amount which is greater than a control or normal level of the analyte normally present in the sample.
- Figures 1A-C show the amino acid sequences of kisspeptin-54 (SEQ ID NO.: l), kisspeptin-53 (SEQ ID NO.:2), and kisspeptin-52 (SEQ ID NO.:3), respectively, including their respective proline variants (i.e., each having the R14P substitution).
- Figure 2 shows a full scan spectrum of Kisspeptin-54. This spectrum shows generation of KP-54 [M+7H]+7 and [M+6H]+6 ions with m/z of 837.5 ⁇ 0.5 and 977.0 ⁇ 0.5, respectively. Details are discussed in Example 3.
- Figure 3 shows an exemplary fragmentation spectrum of KP-54 [M+6HJ+6 ion with m/z of 977.0 ⁇ 0.5. Exemplary fragment ions are observed at m/z of 1083.6 ⁇ 0.5 and 903.1 ⁇ 0.5. Details are discussed in Example 3.
- Figure 4 shows an exemplary fragmentation spectrum of KP-54 [M+7HJ+7 ion with m/z of 837.7 ⁇ 0.5. Exemplary fragment ions are observed at m/z of 902.8 ⁇ 0.5. Details are discussed in Example 3.
- Figure 5 shows a full scan spectrum of Kisspeptin-54(R14P). This spectrum shows generation of KP-54(R14P) [M+6H]+6, [M+5H]+5, and [M+4H]+4 ions with m/z of 967.3 ⁇ 0.5, 1160.6 ⁇ 0.5, and 1450.5 ⁇ 0.5, respectively. Details are discussed in Example 3.
- Figure 6 shows an exemplary fragmentation spectrum of KP-54(R14P) [M+5HJ+ ion with m/z of 1160.6 ⁇ 0.5. Exemplary fragment ions are observed at m/z of 1071.6 ⁇ 0.5. Details are discussed in Example 3.
- Figure 7 shows an exemplary fragmentation spectrum of KP-54(R14P) [M+6HJ+6 ion with m/z of 967.3 ⁇ 0.5. Exemplary fragment ions are observed at m/z of 1071.6 ⁇ 0.5. Details are discussed in Example 3.
- Figure 8 shows a full scan spectrum of Kisspeptin-53. This spectrum shows generation of KP-53 [M+7H]+7, [M+6H]+6, and [M+5H]+5 ions with m/z of 816.9 ⁇ 0.5, 952.7 ⁇ 0.5, and 1143.2 ⁇ 0.5, respectively. Details are discussed in Example 3.
- Figure 9 shows an exemplary fragmentation spectrum of KP-53 [M+5HJ+5 ion with m/z of 1143.2 ⁇ 0.5. Exemplary fragment ions are observed at m/z of 1053.9 ⁇ 0.5. Details are discussed in Example 3.
- Figure 10 shows an exemplary fragmentation spectrum of KP-53 [M+6HJ+6 ion with m/z of 952.7 ⁇ 0.5. Exemplary fragment ions are observed at m/z of 1054.1 ⁇ 0.5 and 878.3 ⁇ 0.5. Details are discussed in Example 3.
- Figure 11 shows an exemplary fragmentation spectrum of KP-53 [M+7HJ+7 ion with m/z of 816.7 ⁇ 0.5. Exemplary fragment ions are observed at m/z of 878.3 ⁇ 0.5. Details are discussed in Example 3.
- Figure 12 shows a full scan spectrum of Kisspeptin-52. This spectrum shows generation of KP-52 [M+6H]+6, [M+5H]+5, and [M+4H]+4 ions with m/z of 926.6 ⁇ 0.5, 1112.0 ⁇ 0.5, and 1389.5 ⁇ 0.5, respectively. Details are discussed in Example 3.
- Figure 13 shows an exemplary fragmentation spectrum of KP-52 [M+5HJ+5 ion with m/z of 1111.9 ⁇ 0.5 ⁇ 0.5. Exemplary fragment ions are observed at m/z of 1278.2 ⁇ 0.5 and 1022.9 ⁇ 0.5. Details are discussed in Example 3.
- Figure 14 shows an exemplary fragmentation spectrum of KP-52 [M+6HJ+6 ion with m/z of 926.8 ⁇ 0.5. Exemplary fragment ions are observed at m/z of 1022.9 ⁇ 0.5. Details are discussed in Example 3.
- Figure 15 shows the detection of KP-52, KP-53, KP-54, and KP-54(IS) in serum from pregnant woman #1 (28 years old, 25 weeks gestation). Details are discussed in Example 4.
- Figure 16 shows the detection of KP-52, KP-53, KP-54, and KP-54(IS) in EDTA plasma from pregnant woman #1 (28 years old, 25 weeks gestation). Details are discussed in Example 4.
- Figure 17 shows the detection of KP-52, KP-53, KP-54, and KP-54(IS) in serum from pregnant woman #2 (21 years old, 28 weeks gestation). Details are discussed in Example 4.
- Figure 18 shows the detection of KP-52, KP-53, KP-54, and KP-54(IS) in EDTA plasma from pregnant woman #2 (21 years old, 28 weeks gestation). Details are discussed in Example 4. DETAILED DESCRIPTION OF THE INVENTION
- Methods are described for measuring the amount of one or more kisspeptin-54- derived peptides in a sample. More specifically, mass spectrometric methods are described for detecting and quantifying one or more kisspeptin-54-derived peptides in a sample. The methods may utilize solid phase extraction and/or liquid chromatography, to perform a purification of selected analytes, combined with methods of mass spectrometry (MS), thereby providing a high-throughput assay system for detecting and quantifying kisspeptin-54- derived peptides in a sample. The preferred embodiments are particularly well suited for application in large clinical laboratories for automated kisspeptin-54-derived peptide quantification assay.
- Suitable test samples for use in methods of the present invention include any test sample that may contain the analyte of interest.
- a sample is a biological sample; that is, a sample obtained from any biological source, such as an animal, a cell culture, an organ culture, etc.
- samples are obtained from a mammalian animal, such as a dog, cat, horse, etc. Particularly preferred mammalian animals are primates, most preferably male or female humans.
- Preferred samples comprise bodily fluids such as blood, plasma, serum, saliva, cerebrospinal fluid, or tissue samples; preferably plasma and serum.
- Such samples may be obtained, for example, from a patient; that is, a living person, male or female, presenting oneself in a clinical setting for diagnosis, prognosis, or treatment of a disease or condition, such as preeclampsia.
- the methods may be used to determine the amount of one or more kisspeptin-54-derived peptides in the sample when the sample was obtained from the biological source (i.e., the amount of one or more endogenous kisspeptin- 54-derived peptides in the sample).
- Kisspeptin-54-derived peptides may be quantitated in patient samples from a pregnant female subject in order to diagnose or predict risk of developing preeclampsia. In diagnosing or predicting risk of preeclampsia, levels of kisspeptin-54-derived peptides from the patient sample are compared to normal levels in pregnant female samples. Elevated levels of kisspeptin-54-derived peptides in a patient sample relative to normal levels indicates the presence of or risk of developing preeclampsia.
- kits for a kisspeptin-54-derived peptide quantitation assay may include a kit comprising the compositions provided herein.
- a kit may include packaging material and measured amounts of an isotopically labeled internal standard, in amounts sufficient for at least one assay.
- the kits will also include instructions recorded in a tangible form (e.g., contained on paper or an electronic medium) for using the packaged reagents for use in a kisspeptin-54-derived peptide quantitation assay.
- Calibration and QC pools for use in embodiments of the present invention are preferably prepared using a matrix similar to the intended sample matrix, provided that the kisspeptin-54-derived peptide is essentially absent.
- samples are acidified prior to analysis.
- Internal standard may be added to the samples prior or subsequent to acidification.
- kisspeptin-54-derived peptides may be enriched relative to one or more other components in the sample (e.g. protein) by various methods known in the art, including for example, liquid chromatography, filtration, centrifugation, thin layer chromatography (TLC), electrophoresis including capillary electrophoresis, affinity separations including immunoaffinity separations, extraction methods including ethyl acetate or methanol extraction, and the use of chaotropic agents or any combination of the above or the like.
- TLC thin layer chromatography
- electrophoresis including capillary electrophoresis
- affinity separations including immunoaffinity separations
- extraction methods including ethyl acetate or methanol extraction, and the use of chaotropic agents or any combination of the above or the like.
- Protein precipitation is one method of preparing a test sample, especially a biological test sample, such as serum or plasma.
- Protein purification methods are well known in the art, for example, Poison et ah, Journal of Chromatography B 2003, 785:263-275, describes protein precipitation techniques suitable for use in methods of the present invention.
- Protein precipitation may be used to remove most of the protein from the sample leaving kisspeptin- 54-derived peptides in the supernatant.
- the samples may be centrifuged to separate the liquid supernatant from the precipitated proteins; alternatively the samples may be filtered to remove precipitated proteins.
- the resultant supernatant or filtrate may then be applied directly to mass spectrometry analysis; or alternatively to further purification steps, such as liquid chromatography, and subsequent mass spectrometry analysis.
- the use of protein precipitation such as, for example, formic acid protein precipitation, may obviate the need for TFLC or other on-line extraction prior to mass spectrometry or HPLC and mass spectrometry.
- Another method of sample purification that may be used prior to mass spectrometry is liquid chromatography (LC). Certain methods of liquid chromatography, including HPLC, rely on relatively slow, laminar flow technology.
- the chromatographic column typically includes a medium (i.e., a packing material) to facilitate separation of chemical moieties (i.e., fractionation).
- the medium may include minute particles.
- the particles typically include a bonded surface that interacts with the various chemical moieties to facilitate separation of the chemical moieties.
- One suitable bonded surface is a hydrophobic bonded surface such as an alkyl bonded or a cyano bonded surface.
- Alkyl bonded surfaces may include C-4, C-8, C-12, or C-18 bonded alkyl groups.
- the column is a C-18 column.
- the chromatographic column includes an inlet port for receiving a sample and an outlet port for discharging an effluent that includes the fractionated sample.
- the sample may be supplied to the inlet port directly, or from a SPE column, such as an on-line extraction column or a TFLC column.
- an on-line filter may be used ahead of the SPE column and or HPLC column to remove particulates and phospholipids in the samples prior to the samples reaching the SPE and/or HPLC columns.
- a 0.2 ⁇ or 0.45 ⁇ micro-spin cellulose acetate delipidation filter is used as such an off-line filter.
- the sample may be applied to the LC column at the inlet port, eluted with a solvent or solvent mixture, and discharged at the outlet port.
- a solvent or solvent mixture eluted with a solvent or solvent mixture
- Different solvent modes may be selected for eluting the analyte(s) of interest.
- liquid sample eluted with a solvent or solvent mixture
- Different solvent modes may be selected for eluting the analyte(s) of interest.
- chromatography may be performed using a gradient mode, an isocratic mode, or a polytypic (i.e. mixed) mode.
- a gradient mode an isocratic mode
- a polytypic (i.e. mixed) mode a polytypic (i.e. mixed) mode.
- the separation of materials is effected by variables such as choice of eluent (also known as a "mobile phase"), elution mode, gradient conditions, temperature, etc.
- an analyte may be purified by applying a sample to a column under conditions where the analyte of interest is reversibly retained by the column packing material, while one or more other materials are not retained.
- a first mobile phase condition can be employed where the analyte of interest is retained by the column, and a second mobile phase condition can subsequently be employed to remove retained material from the column, once the non-retained materials are washed through.
- an analyte may be purified by applying a sample to a column under mobile phase conditions where the analyte of interest elutes at a differential rate in comparison to one or more other materials. Such procedures may enrich the amount of one or more analytes of interest relative to one or more other components of the sample.
- HPLC is conducted with a polar embedded analytical column chromatographic system.
- a C-18 BEH (ethylene bridged hybrid) analytical column e.g., an XBridge C18 BEH analytical column from Waters Inc. (2.5 x 50 mm, 5 ⁇ particle size), or equivalent
- HPLC is performed using HPLC Grade 0.2% aqueous formic acid as solvent A, and 0.2% formic acid in acetonitrile as solvent B.
- valves and connector plumbing By careful selection of valves and connector plumbing, two or more chromatography columns may be connected as needed such that material is passed from one to the next without the need for any manual steps.
- the selection of valves and plumbing is controlled by a computer pre-programmed to perform the necessary steps.
- the chromatography system is also connected in such an on-line fashion to the detector system, e.g., an MS system.
- the detector system e.g., an MS system.
- TFLC may be used for purification of kisspeptin-54-derived peptides prior to mass spectrometry.
- samples may be extracted using a TFLC column which captures the analyte.
- the analyte is then eluted and transferred on-line to an analytical HPLC column.
- sample extraction may be accomplished with a TFLC extraction cartridge may be accomplished with a large particle size (e.g., 25 ⁇ or larger, such as 50 ⁇ , particle size) packed column.
- Sample eluted off of this column is then transferred on-line to an HPLC analytical column for further purification prior to mass spectrometry. Because the steps involved in these chromatography procedures may be linked in an automated fashion, the requirement for operator involvement during the purification of the analyte can be minimized. This feature may result in savings of time and costs, and eliminate the opportunity for operator error.
- the methods include immunopurifying kisspeptin-54-derived peptides prior to analysis.
- the immunopurification step may be performed using any of the immunopurification methods well known in the art. Often the immunopurification procedure utilizes antibodies bound, conjugated, immobilized or otherwise attached to a solid support, for example a column, well, tube, capsule, particle or the like. Generally,
- immunopurification methods involve (1) incubating a sample containing the analyte of interest with antibodies such that the analyte binds to the antibodies, (2) performing one or more washing steps, and (3) eluting the analyte from the antibodies.
- the incubation step of the immunopurification is performed with the antibodies free in solution and the antibodies are subsequently bound or attached to a solid surface prior to the washing steps.
- this can be achieved using a primary antibody that is an anti- kisspeptin-54-derived peptide antibody and a secondary antibody attached to a solid surface that has an affinity to the primary anti- kisspeptin-54- derived peptide antibody.
- the primary antibody is bound to the solid surface prior to the incubation step.
- Appropriate solid supports include without limitation tubes, slides, columns, beads, capsules, particles, gels, and the like.
- the solid support is a multi-well plate, such as, for example, a 96 well plate, a 384-well plate or the like.
- the solid support are sepharose or agarose beads or gels.
- antibodies for example, an anti- kisspeptin-54-derived peptide antibody or a secondary antibody
- covalent or non-covalent linkages adsorption, affinity binding, ionic linkages and the like.
- antibodies are coupled using CNBr, for example the antibodies may be coupled to CNBr activated sepharose.
- the antibody is attached to the solid support through an antibody binding protein such as protein A, protein G, protein A/G, or protein L.
- the washing step of the immunopurification methods generally involve washing the solid support such that one or more kisspeptin-54-derived peptides remain bound to the anti- kisspeptin-54-derived peptide antibodies on the solid support.
- the elution step of the immunopurification generally involves the addition of a solution that disrupts the binding of kisspeptin-54-derived peptides to the anti-kisspeptin-54-derived peptide antibodies.
- Exemplary elution solutions include organic solutions (such as ethanol), salt solutions, and high or low pH solutions.
- immunopurification is performed using immunoparticles having anti-kisspeptin-54-derived peptide antibodies.
- the test sample possibly containing one or more kisspeptin-54-derived peptides and the immunoparticles are mixed in a tube for incubation and binding of kisspeptin-54-derived peptides to the anti-kisspeptin-54-derived peptide antibodies attached to the immunoparticles; the tube is centrifuged leaving the immunoparticles in a pellet; the supernatant is removed; the immunoparticles are washed one or more times by adding a solution to the pellet and recentrifuging; and the bound kisspeptin-54-derived peptides are eluted by adding an elution solution to the immunoparticles, the tube is centrifuged leaving the immunoparticles in a pellet; and the
- the immunopurification is performed using a column or cartridge that contains immunoparticles having anti-kisspeptin-54-derived peptide antibodies.
- the such column or cartridge is configured and arranged in a manner to allow solutions to flow through while keeping the immunoparticles contained therein.
- the solution is forced through the column or cartridge by gravity,
- the immunopurification may be performed by affinity chromatography; preferably automated affinity chromatography.
- kisspeptin-54 in patient samples i.e., serum or plasma
- patient samples i.e., serum or plasma
- This degradation if not controlled or accounted for, could result in erroneously low analytical results.
- radioimmunoassays which rely on binding of the C-terminus of KP-54 would not account for that portion of KP-54 originally in the patient sample which has since degraded into KP-53 or KP-52.
- one aspect of the present invention utilizes antibodies specific for the N-terminus of kisspeptin-54-derived peptides for immunopurification and/or immunoassay.
- N-terminus specific antibodies KP-54 and its degradation products K-53 and K-52 are captured for further analysis.
- patient samples may be treated with one or more agents or subject to physical conditions which inhibit or prevent KP-54 degradation prior to KP-54 purification and analysis.
- patient serum or plasma samples may be acidified, such as with formic acid, to inhibit or prevent degradation.
- patient serum or plasma samples may be subject to any protein precipitation technique known in the art (such as treatment with methanol) to inhibit or prevent degradation.
- KP-54 Regardless of purification methods employed and/or steps taken to reduce or inhibit KP-54 degradation, methods of analyzing patient samples may be employed which account for KP-54 degradation by simultaneously analyzing the sample for other kisspeptin-54- derived peptides. Specifically, patient samples can be simultaneously analyzed for KP-54, KP-53, and KP-52 (or their proline varients). The combined amounts of KP-54 and one or both of KP-53 and KP-52 may provide a more diagnostically useful indication of KP-54 originally present in the patient sample.
- kisspeptin-54-derived peptides may be ionized by any method known to the skilled artisan.
- Mass spectrometry is performed using a mass spectrometer, which includes an ion source for ionizing the fractionated sample and creating charged molecules for further analysis.
- ionization of the sample may be performed by electron ionization, chemical ionization, electrospray ionization (ESI), photon ionization, atmospheric pressure chemical ionization (APCI), photoionization, atmospheric pressure photoionization (APPI), Laser diode thermal desorption (LDTD), fast atom bombardment (FAB), liquid secondary ionization (LSI), matrix assisted laser desorption ionization (MALDI), field ionization, field desorption, thermospray/plasmaspray ionization, surface enhanced laser desorption ionization (SELDI), inductively coupled plasma (ICP) and particle beam ionization.
- ESI electron ionization
- APCI atmospheric pressure chemical ionization
- APPI atmospheric pressure photoionization
- LDTD Laser diode thermal desorption
- FAB fast atom bombardment
- LSI liquid secondary ionization
- MALDI matrix assisted laser desorption ionization
- field ionization
- a kisspeptin-54-derived peptide may be ionized in positive or negative mode.
- kisspeptin-54-derived peptides are ionized by ESI (such as by heated ESI) in positive mode.
- the positively or negatively charged ions thereby created may be analyzed to determine a mass- to-charge ratio.
- Suitable analyzers for determining mass-to-charge ratios include quadrupole analyzers, ion traps analyzers, and time-of-flight analyzers. Exemplary ion trap methods are described in Bartolucci, et ⁇ , Rapid Commun. Mass Spectrom. 2000, 14:967-73.
- the ions may be detected using several detection modes. For example, selected ions may be detected, i.e. using a selective ion monitoring mode (SIM), or alternatively, mass transitions resulting from collision induced dissociation or neutral loss may be monitored, e.g., multiple reaction monitoring (MRM) or selected reaction monitoring (SRM).
- SIM selective ion monitoring mode
- MRM multiple reaction monitoring
- SRM selected reaction monitoring
- the mass-to-charge ratio is determined using a quadrupole analyzer.
- a quadrupole analyzer For example, in a "quadrupole” or “quadrupole ion trap” instrument, ions in an oscillating radio frequency field experience a force proportional to the DC potential applied between electrodes, the amplitude of the RF signal, and the mass/charge ratio. The voltage and amplitude may be selected so that only ions having a particular mass/charge ratio travel the length of the quadrupole, while all other ions are deflected.
- quadrupole instruments may act as both a “mass filter” and as a “mass detector” for the ions injected into the instrument.
- a precursor ion also called a parent ion
- the precursor ion subsequently fragmented to yield one or more fragment ions (also called daughter ions or product ions) that are then analyzed in a second MS procedure.
- fragment ions also called daughter ions or product ions
- the MS/MS technique may provide an extremely powerful analytical tool.
- the combination of filtration/fragmentation may be used to eliminate interfering substances, and may be particularly useful in complex samples, such as biological samples.
- Alternate modes of operating a tandem mass spectrometric instrument include product ion scanning and precursor ion scanning.
- product ion scanning and precursor ion scanning.
- Chromatographic-Mass Spectrometric Food Analysis for Trace Determination of Pesticide Residues Chapter 8 (Amadeo R. Fernandez- Alba, ed., Elsevier 2005) (387).
- the results of an analyte assay may be related to the amount of the analyte in the original sample by numerous methods known in the art. For example, given that sampling and analysis parameters are carefully controlled, the relative abundance of a given ion may be compared to a table that converts that relative abundance to an absolute amount of the original molecule. Alternatively, external standards may be run with the samples, and a standard curve constructed based on ions generated from those standards. Using such a standard curve, the relative abundance of a given ion may be converted into an absolute amount of the original molecule. In certain preferred embodiments, an internal standard is used to generate a standard curve for calculating the quantity of a kisspeptin-54-derived peptide.
- an "isotopic label” produces a mass shift in the labeled molecule relative to the unlabeled molecule when analyzed by mass spectrometric techniques.
- Suitable labels include deuterium ( H), C, and N.
- One or more isotopic labels can be incorporated at one or more positions in the molecule and one or more kinds of isotopic labels can be used on the same isotopically labeled molecule.
- One or more steps of the methods may be performed using automated machines.
- one or more purification steps are performed on-line, and more preferably all of the purification and mass spectrometry steps may be performed in an on-line fashion.
- CAD collision activated dissociation
- one or more kisspeptin-54-derived peptides in a sample are detected and/or quantified using MS/MS as follows.
- Samples are preferably subjected to SPE, then subjected to liquid chromatography, preferably HPLC; the flow of liquid solvent from a chromatographic column enters the heated nebulizer interface of an MS/MS analyzer; and the solvent/analyte mixture is converted to vapor in the heated charged tubing of the interface.
- one or more analytes i.e., one or more kisspeptin-54-derived peptides
- the ions e.g.
- Quadrupoles 1 and 3 are mass filters, allowing selection of ions (i.e., selection of "precursor” and “fragment” ions in Ql and Q3, respectively) based on their mass to charge ratio (m/z).
- Quadrupole 2 (Q2) is the collision cell, where ions are fragmented.
- the first quadrupole of the mass spectrometer (Ql) selects for molecules with the mass to charge ratios of a kisspeptin-54-derived peptide.
- Precursor ions with the correct mass/charge ratios are allowed to pass into the collision chamber (Q2), while unwanted ions with any other mass/charge ratio collide with the sides of the quadrupole and are eliminated.
- Precursor ions entering Q2 collide with neutral argon gas molecules and fragment.
- the fragment ions generated are passed into quadrupole 3 (Q3), where the fragment ions of a kisspeptin-54-derived peptide are selected while other ions are eliminated. This process can be repeated as often as necessary to analyze as many kisspeptin-54-derived peptides as desired.
- ions collide with the detector they produce a pulse of electrons that are converted to a digital signal.
- the acquired data is relayed to a computer, which plots counts of the ions collected versus time.
- the resulting mass chromatograms are similar to chromatograms generated in traditional HPLC-MS methods.
- the areas under the peaks corresponding to particular ions, or the amplitude of such peaks may be measured and correlated to the amount of the analyte of interest.
- the area under the curves, or amplitude of the peaks, for fragment ion(s) and/or precursor ions are measured to determine the amount of a kisspeptin-54-derived peptide.
- the relative abundance of a given ion may be converted into an absolute amount of the original analyte using calibration standard curves based on peaks of one or more ions of an internal molecular standard.
- a 100 serum or EDTA plasma patient sample was mixed with 300 ⁇ ⁇ of methanol containing isotope labeled kisspeptin-54 as an internal standard.
- the protein precipitate was removed via centrifugation and the supernatant was subjected to LC-MS and LC-MS/MS as described in the following Examples.
- Example 2 Extraction of isspeptin-54-Derived Peptides From Samples Using Liquid Chromato graphy
- the analytes and internal standard were isolated from the serum extract using a Waters HLB C18 (2.1 x 20 mm, 25 ⁇ particle size) solid phase extraction cartridge. After injection of the extract, the cartridge was washed with 90% solvent A (water + 0.2% formic acid) and 10% solvent B (acetonitrile + 0.2% formic acid). The extraction cartridge retained kisspeptin-54 while ions and very polar molecules flowed through.
- Analytical separation was performed with a Waters X-Bridge C18 BEH analytical column (2.5 x 50 mm, 5 ⁇ particle size) using a fast, multiphase gradient of increasing solvent B in solvent A.
- the HPLC gradient started with a 5 % organic modifier which was ramped to 35 % in approximately 180 seconds.
- MS was performed using a Thermo-Fisher TSQ Quantum Ultra triple quadrupole. Ionization was conducted with a heated electrospray ionization (HESI) probe. Multiply charged ions of several kisspeptin-54-derived peptides were observed. Single MS spectra showing multiply charged kisspeptin-54-related peptide ions are seen in Figure 2 (KP-54), Figure 5 (KP-54 (proline variant)), Figure 8 (KP-53), and Figure 12 (KP-52), respectively. Several major ions, several of which are seen in these figures, are compiled in Table 1.
- KP-52 5+ and 6+ precursor ions were fragmented, with exemplary MS/MS spectra seen in Figures 13 and 14. Additionally, isotopically labeled KP- 54 were ionized and fragmented as discussed above (spectra not shown). The m/z ratios of several of the observed major fragment ions are compiled and listed in Table 2. Table 2. Exemplary fragment ions observed for several Kisspeptin-54-derived peptides
- MS/MS was performed using a Thermo-Fisher TSQ Quantum Ultra triple quadrupole MS/MS system equipped with a heated electrospray ionization (HESI) probe (Thermo Electron Corporation).
- HESI heated electrospray ionization
- Electron were used in the Examples described herein: TSQ Ultra Quantum V 1.4.1 or newer, Xcalibur V 2.0 or newer, and LCQuan V 2.5 or newer.
- Liquid solvent/analyte exiting the analytical column flowed to the heated nebulizer interface of the MS/MS analyzer. The solvent/analyte mixture was converted to vapor in the heated tubing of the interface.
- Kisspeptin-54-derived peptide ions passed to the first quadrupole (Ql), which selected KP-54 ions with a m/z of 977.0 ⁇ 0.5, KP-53 ions with a m/z of 952.9 ⁇ 0.5, KP-52 ions with a m/z of 926.9 ⁇ 0.5, or isotopically labeled KP-54 (IS) ions with a m/z of 980.3 ⁇ 0.5.
- the following mass transitions were used for detection and quantitation during validation on positive polarity.
- Exemplary mass chromatograms for the simultaneous quantitation of KP-52, KP-53, KP-54, and KP-54(IS) from analysis of two patient samples are shown in Figures 15 (patient #1-28 years old, 25 weeks gestation, serum) and 16 (patient #1-28 years old, 25 weeks gestation, EDTA plasma), 17 (patient #2-21 years old, 25 weeks gestation, serum), and 18 (patient #2-21 years old, 25 weeks gestation, EDTA plasma).
- a comparison of the mass chromatograms from serum versus EDTA plasma samples shows that serum samples are more susceptible to formation of shorter forms of kisspeptin-54 derived peptides.
- initial patient samples are enriched by capture and extraction of kisspeptin-54-derived peptides with antibodies highly specific for the N-terminal portion of Kisspeptin.
- KP-54 has been found to degrade in samples at the C-terminus, thus allowing use of N-terminal specific antibodies for capture and enrichment of kisspeptin-54-derived peptides, including KP-54, KP-53, KP-52, and isotopic and chemically modified variants thereof.
- N-terminal specific antibodies for capture and enrichment of kisspeptin-54-derived peptides, including KP-54, KP-53, KP-52, and isotopic and chemically modified variants thereof.
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19167826.7A EP3557605B1 (en) | 2011-11-23 | 2012-11-20 | Kisspeptin-54 detection by tandem mass spectrometry |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161563435P | 2011-11-23 | 2011-11-23 | |
PCT/US2012/066093 WO2013078222A1 (en) | 2011-11-23 | 2012-11-20 | Kisspeptin-54 detection by tandem mass spectrometry |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19167826.7A Division EP3557605B1 (en) | 2011-11-23 | 2012-11-20 | Kisspeptin-54 detection by tandem mass spectrometry |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2783388A1 true EP2783388A1 (en) | 2014-10-01 |
EP2783388A4 EP2783388A4 (en) | 2015-12-09 |
Family
ID=48470257
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19167826.7A Active EP3557605B1 (en) | 2011-11-23 | 2012-11-20 | Kisspeptin-54 detection by tandem mass spectrometry |
EP12851916.2A Ceased EP2783388A4 (en) | 2011-11-23 | 2012-11-20 | Kisspeptin-54 detection by tandem mass spectrometry |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19167826.7A Active EP3557605B1 (en) | 2011-11-23 | 2012-11-20 | Kisspeptin-54 detection by tandem mass spectrometry |
Country Status (4)
Country | Link |
---|---|
US (6) | US8916680B2 (en) |
EP (2) | EP3557605B1 (en) |
JP (1) | JP6444736B2 (en) |
WO (1) | WO2013078222A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210407269A1 (en) * | 2007-06-29 | 2021-12-30 | Quest Diagnostics Investment Incorporated | Analysis of amino acids in body fluid by liquid chromotography-mass spectrometry |
JP6444736B2 (en) * | 2011-11-23 | 2018-12-26 | クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド | Detection of kisspeptin-54 by tandem mass spectrometry |
CN108348818B (en) | 2015-08-13 | 2021-05-28 | 沃特世科技公司 | Nickel-cobalt alloy material devices and components |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0233973B1 (en) | 1986-02-26 | 1990-12-27 | Hewlett-Packard GmbH | Mixture of amino acid derivatives, process of producing the mixture and use of the mixture for quantitative determination of the amino acids |
US5534440A (en) | 1991-02-22 | 1996-07-09 | Biomedical Research Centre Limited | Compounds and methods for sequencing amino acids |
US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
PT700521E (en) | 1993-05-28 | 2003-10-31 | Baylor College Medicine | METHOD AND MASS SPECTROMETER FOR DESSORING AND IONIZATION OF ANALYZES |
US5559038A (en) | 1994-05-04 | 1996-09-24 | The Regents Of The University Of Colorado | Gas chromatography/mass spectrometry determination of oxidized sulfhydryl amino acids |
US5772874A (en) | 1995-11-02 | 1998-06-30 | Cohesive Technologies, Inc. | High performance liquid chromatography method and apparatus |
CA2242885C (en) | 1996-01-19 | 2006-08-15 | Cohesive Technologies, Inc. | High performance liquid chromatography method and apparatus |
US5780243A (en) | 1996-06-28 | 1998-07-14 | Thaco Research, Ltd. | Methods for the quantitative analysis of organic compounds |
US5885841A (en) | 1996-09-11 | 1999-03-23 | Eli Lilly And Company | System and methods for qualitatively and quantitatively comparing complex admixtures using single ion chromatograms derived from spectroscopic analysis of such admixtures |
GB9717926D0 (en) | 1997-08-22 | 1997-10-29 | Micromass Ltd | Methods and apparatus for tandem mass spectrometry |
US6040575A (en) | 1998-01-23 | 2000-03-21 | Analytica Of Branford, Inc. | Mass spectrometry from surfaces |
EP1113269B1 (en) * | 1999-12-29 | 2006-10-18 | PerkinElmer Life Sciences, Inc. | Test tray, kit and methods for screening body fluids of newborns by tandem mass spectrometry |
US20020182660A1 (en) * | 2000-02-18 | 2002-12-05 | Fong Kei-Lai L. | N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43) |
US6692971B2 (en) | 2000-04-17 | 2004-02-17 | University Of Utah Research Foundation | Method of analyzing dicarboxylic acids |
EP1330654B1 (en) | 2000-10-23 | 2006-03-08 | Genetics Institute, LLC | Acid-labile isotope-coded extractant (alice) in mass spectometric analysis |
EP1428835B1 (en) * | 2001-09-19 | 2007-04-18 | Takeda Pharmaceutical Company Limited | Antibody against metastin and use of the same in the diagnosis of pregnancy |
EP1430307A2 (en) | 2001-09-27 | 2004-06-23 | Oxford GlycoSciences (UK) Ltd, Attn: Mary Gadsden | A method of protein analysis |
US20030153007A1 (en) | 2001-12-28 | 2003-08-14 | Jian Chen | Automated systems and methods for analysis of protein post-translational modification |
EP2317307B1 (en) | 2002-02-14 | 2013-11-20 | Ajinomoto Co., Inc. | Method of analyzing amino- and/or imino-functional compounds, and analytical reagent |
US20060134109A1 (en) | 2002-09-09 | 2006-06-22 | Nura Inc. | G protein coupled receptors and uses thereof |
US6977143B1 (en) | 2003-09-08 | 2005-12-20 | Quest Diagnostics Investments Incorporated | Determination of testosterone by mass spectrometry |
JP4835036B2 (en) | 2004-05-17 | 2011-12-14 | 味の素株式会社 | Highly sensitive detection method for organic compounds |
EP1750126B1 (en) | 2004-05-26 | 2015-09-16 | Ajinomoto Co., Inc. | Method and apparatus for analyzing aminofunctional compound |
US7700364B2 (en) * | 2004-10-12 | 2010-04-20 | Quest Diagnostics Investments Incorporated | Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry |
US8969089B2 (en) * | 2004-10-12 | 2015-03-03 | Quest Diagnostics Investments, Inc. | Analysis of amino acids in body fluid by liquid chromatography-mass spectrometry |
US20060183238A1 (en) | 2005-02-09 | 2006-08-17 | Applera Corporation | Amine-containing compound analysis methods |
WO2007003344A2 (en) | 2005-06-30 | 2007-01-11 | Biocrates Life Sciences Ag | Device for quantitative analysis of a metabolite profile |
JP2007024822A (en) | 2005-07-21 | 2007-02-01 | Aska Pharmaceutical Co Ltd | Discriminating method of male menopause or depression |
JP5144273B2 (en) * | 2005-11-14 | 2013-02-13 | 第一三共株式会社 | Polypeptide detection or quantification method and apparatus |
JP2007163423A (en) | 2005-12-16 | 2007-06-28 | Ajinomoto Co Inc | Amino acid analytical method by mass spectrometer |
CN1825113A (en) | 2006-03-21 | 2006-08-30 | 扬州大学 | PAABSF column front derivatizing process of amino-acid |
EP2898900B1 (en) * | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
JP5317336B2 (en) * | 2009-02-23 | 2013-10-16 | 国立大学法人東北大学 | Peptide for evaluation, artificial standard protein, and protein quantification method for protein quantification using mass spectrometer |
US8945933B2 (en) * | 2009-10-12 | 2015-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Liquid chromatography-mass spectrometry methods for multiplexed detection and quantitation of free amino acids |
AU2011240039B2 (en) * | 2010-04-13 | 2017-01-19 | Mycartis Nv | Biomarkers for hypertensive disorders of pregnancy |
JP6444736B2 (en) * | 2011-11-23 | 2018-12-26 | クエスト ダイアグノスティックス インヴェストメンツ インコーポレイテッド | Detection of kisspeptin-54 by tandem mass spectrometry |
JP6259734B2 (en) | 2014-08-27 | 2018-01-10 | 京楽産業.株式会社 | Game machine |
-
2012
- 2012-11-20 JP JP2014543542A patent/JP6444736B2/en active Active
- 2012-11-20 EP EP19167826.7A patent/EP3557605B1/en active Active
- 2012-11-20 WO PCT/US2012/066093 patent/WO2013078222A1/en active Application Filing
- 2012-11-20 US US13/682,304 patent/US8916680B2/en active Active
- 2012-11-20 EP EP12851916.2A patent/EP2783388A4/en not_active Ceased
-
2014
- 2014-12-10 US US14/565,805 patent/US9583322B2/en active Active
-
2017
- 2017-02-27 US US15/443,645 patent/US9874569B2/en active Active
-
2018
- 2018-01-19 US US15/875,850 patent/US10203337B2/en active Active
-
2019
- 2019-01-07 US US16/241,291 patent/US10962550B2/en active Active
- 2019-02-11 US US16/272,940 patent/US10712348B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP6444736B2 (en) | 2018-12-26 |
US20180149662A1 (en) | 2018-05-31 |
US9583322B2 (en) | 2017-02-28 |
WO2013078222A1 (en) | 2013-05-30 |
US20170176451A1 (en) | 2017-06-22 |
US20150115150A1 (en) | 2015-04-30 |
US10203337B2 (en) | 2019-02-12 |
US10962550B2 (en) | 2021-03-30 |
JP2015501932A (en) | 2015-01-19 |
US20190242902A1 (en) | 2019-08-08 |
US20190145983A1 (en) | 2019-05-16 |
US20130165627A1 (en) | 2013-06-27 |
EP2783388A4 (en) | 2015-12-09 |
EP3557605A1 (en) | 2019-10-23 |
US9874569B2 (en) | 2018-01-23 |
EP3557605B1 (en) | 2021-07-14 |
US8916680B2 (en) | 2014-12-23 |
US10712348B2 (en) | 2020-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3511973B1 (en) | Quantitation of insulin by mass spectrometry | |
US11346845B2 (en) | C peptide detection by mass spectrometry | |
US20220349897A1 (en) | Amyloid beta detection by mass spectrometry | |
US10712348B2 (en) | Kisspeptin-54 detection by tandem mass spectrometry | |
WO2011084751A1 (en) | Glucagon detection and quantitation by mass spectrometry | |
WO2019178562A1 (en) | Methods for detecting chromogranin a by mass spectrometry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140520 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20151106 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: G01N 33/68 20060101ALI20151102BHEP Ipc: H01J 49/26 20060101AFI20151102BHEP |
|
17Q | First examination report despatched |
Effective date: 20160715 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20190123 |